Bacticent antimicrobial coating technologies transform your medical device into a powerful weapon in the fight against healthcare associated infections.
Bacticent technology provides a broad spectrum of efficacy with a well-characterized drug, making it a major differentiator for your medical device.
Antimicrobial surface treatments add a critical layer of protection to medical devices, reducing microbial colonization and lower infection risks, including CLABSIs. All while delivering broad-spectrum, continuous defense between disinfections.
Adaptable for a variety of antimicrobial drugs, compatible with most relevant device substrates and custom tailored to meet or exceed your required elution and drug-effectiveness timelines, Bacticent is an ideal choice for indwelling catheters, central venous catheters, dialysis catheters, needleless connectors and other devices designed to combat gram-positive or gram-negative bacteria.
Lowers infection risk by reducing microbial colonization on medical devices such as connectors or catheters.
Provides ongonig protection between standard disinfections.
Broad-spectrum efficacy against the most common healthcare pathogens.
Bacticent technology fits seamlessly into workflows without changing clinical use.
Durable and compatible with disinfectants and connector materials.
Click the graph to expand the image
Titanium substrates were coated with a Bacticent AM130 Antimicrobial Chlorhexidine Acetate Coating and were incubated in 10 mM phosphate buffered saline at 37°C with gentle agitation (~30-50 RPM). The buffer was exchanged at the intervals seen in the corresponding graph, and the elution solutions were analyzed by HPLC for chlorhexidine concentration.
The Bacticent AM130 Antimicrobial Coating exhibited sustained elution of chlorhexidine sufficient to be effective against a variety of microbes (eg. S. Aureus, E. Coli, E. Faecalis) over a period of 14 days as indicated by the MIC line for S. Aureus.
At any given time, the CDC estimates that one in of 31 hospitalized patients is affected by a Healthcare Associated Infection (HAI), and that preventing these infections could save an estimated $30 billion in medical costs.
One of the most effective ways to combat HAIs is with antimicrobial coating applications, but matching a device to a surface treatment that’s optimized for its substrate and the best anti-infective compound can be a daunting process for your in-house team.
Partnering with Harland involves a stage-gated process tailored specifically to the requirements of your device application. We’ll work with you to understand the infection-reduction and elution-profile demands of your device, and then develop a Bacticent program customized to those needs.
Bacticent’s flexible development process allows Harland to engineer an antimicrobial delivery system compatible with most relevant device substrates and capable of utilizing a variety of antimicrobial compounds like chlorhexidine or rifampin.
Through out stage-gated development process, we tailor each Bacticent program to your device’s unique needs, optimizing infection reduction and elution performance.
Bacticent is compatible with hydrophilic coatings to increase surface lubricity.
Automated coating systems for applying and curing medical device coatings.
Tell us more about your device: